English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  To investigate the impact of renal function on the safety and efficacy of insulin glargine 300 U/mL (Gla‐300) and insulin glargine 100 U/mL (Gla‐100).    Materials and Methods  A meta‐analysis was performed using pooled 6‐month data from the EDITION 1, 2 and 3 trials ( N  = 2496). Eligible participants, aged ≥18 years with a diagnosis of type 2 diabetes (T2DM), were randomized to receive once‐daily evening injections of Gla‐300 or Gla‐100. Pooled results were assessed by two renal function subgroups: estimated glomerular filtration rate (eGFR) <60 and ≥60 mL/min/1.73 m 2 .    Results  The decrease in glycated haemoglobin (HbA1c) after 6 months and the proportion of individuals with T2DM achieving HbA1c targets were similar in the Gla‐300 and Gla‐100 groups, for both renal function subgroups. There was a reduced risk of nocturnal (12:00‐5:59  am ) confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia with Gla‐300 in both renal function subgroups (eGFR <60 mL/min/1.73 m 2 : relative risk [RR] 0.76 [95% confidence interval {CI} 0.62‐0.94] and eGFR ≥60 mL/min/1.73 m 2 : RR 0.75 [95% CI 0.67‐0.85]). For confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycaemia at any time of day (24 hours) the hypoglycaemia risk was lower with Gla‐300 vs Gla‐100 in both the lower (RR 0.94 [95% CI 0.86‐1.03]) and higher (RR 0.90 [95% CI 0.85‐0.95]) eGFR subgroups.    Conclusions  Gla‐300 provided similar glycaemic control to Gla‐100, while indicating a reduced overall risk of confirmed (≤3.9 and <3.0 mmol/L [≤70 and <54 mg/dL]) or severe hypoglycaemia, with no significant difference between renal function subgroups.

diabetes, obesity and metabolism

Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild‐to‐moderate renal impairment